Korean J Hematol.  2002 Feb;37(1):24-30.

Effect of Fixed Dose of G-CSF on Mobilization and Engraftment of Peripheral Blood Stem Cells in High Dose Chemotherapy

  • 1Department of Hematology-oncology, College of Medicine, Ajou University Hospital, Suwon, Korea. hughkim@unitel.co.kr


Recently, the use of peripheral blood stem cell (PBSC) instead of bone marrow stem cells is associated with faster engraftment and reduced transplantation related complications. Several studies revealed that intermediate dose of Granulocyte-Colony Stimulating Factor (G-CSF) (less than 5ng/kg) is enough to be effective in the mobilization of stem cells for autologous transplantation. Also, to simplify mobilization procedure and reduce the cost for mobilization, a fixed dose of G- CSF (250 ng/patient/day) needs to be tested for its clinical feasibility.
Patients with various malignant diseases were referred to the Ajou University Hospital (N=106) for PBSC transplantation with high dose chemotherapy. All patients were given fixed dose of G-CSF (250 ng/patient/ day) for mobilization and engraftment.
Except for a few complaints of mild bone pain, all of the patients tolerated the treatment well during the mobilization. Early engraftment and yield of mobilization were related to the accumulated cycle of prior chemotherapy and prior radiotherapy.
Fixed dose of G-CSF without accordance to the body weight of the patient showed no significant difference compared to the current reports on the mobilization of stem cells and engraftment after transplantation. The total number of chemotherapy cycles exposed before transplantation and the prior radiation therapy history were certainly the most important influencing factor in stem cell transplantation and mobilization.


Granulocyte-Colony Stimulating Factor (G-CSF); High dose chemotherapy; Autologous peripheral blood stem cell transplantation
Full Text Links
  • KJH
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr